Laurene Isip - Integra LifeSciences Vice Relations

Integra LifeSciences Management Efficiency

The company has return on total asset (ROA) of 0.0351 % which means that it generated a profit of $0.0351 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0147 %, meaning that it created $0.0147 on every $100 dollars invested by stockholders. Integra LifeSciences' management efficiency ratios could be used to measure how well Integra LifeSciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.04 in 2024. Return On Capital Employed is likely to gain to 0.05 in 2024. At this time, Integra LifeSciences' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2 B in 2024, whereas Total Current Liabilities is likely to drop slightly above 158.9 M in 2024.

Similar Executives

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey. Integra Lifesciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 3800 people. Integra LifeSciences Holdings (IART) is traded on NASDAQ Exchange in USA. It is located in 1100 Campus Road, Princeton, NJ, United States, 08540 and employs 3,946 people. Integra LifeSciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Integra LifeSciences Leadership Team

Integra Stock Performance Indicators

Additional Tools for Integra Stock Analysis